Samartzis Konstantinos, Thomakos Nikolaos, Liontos Michael, Kollia Dimitra, Malakasis Anastasios, Haidopoulos Dimitrios, Bamias Aristotelis, Rodolakis Alexandros, Loutradis Dimitrios
Division of Gynecologic Oncology,1st Department of Obstetrics & Gynecology, University of Athens, 'Alexandra' Hospital, Athens, Greece.
J BUON. 2018 Dec;23(7):19-23.
Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease.
卵巢癌是女性癌症相关死亡的主要原因，通常在晚期伴有弥漫性腹膜癌时才被诊断出来。由于它主要局限于腹腔，即使在复发后，也是局部区域治疗的理想靶点。晚期卵巢癌的标准治疗策略是细胞减灭术，然后进行全身化疗。作为辅助治疗的腹腔内化疗已显示出对卵巢癌患者生存有益。与单纯腹腔内化疗相比，热灌注腹腔内化疗（HIPEC）有多个优势。这促使在复发性疾病的一线和二线治疗中，采用细胞减灭术（CRS）联合HIPEC来治疗卵巢癌。
